Factors influencing retention in care after starting antiretroviral therapy in a rural south african programme

PLoS ONE

Volumn 6, Issue 5, 2011, Pages

  Boyles, Tom H ^a,b   Wilkinson, Lynne S ^a   Leisegang, Rory ^b   Maartens, Gary ^b  

^a Madwaleni Hospital   (South Africa)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; COTRIMOXAZOLE; DIDANOSINE; EFAVIRENZ; ISONIAZID; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; MULTIVITAMIN; NEVIRAPINE; STAVUDINE; ZIDOVUDINE;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; CONTROLLED STUDY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEALTH CARE MANAGEMENT; HEALTH PROGRAM; HEALTH SERVICE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PATIENT COUNSELING; PROFESSIONAL PRACTICE; PROSPECTIVE STUDY; SOUTH AFRICA; TREATMENT OUTCOME; CD4+ T LYMPHOCYTE; CYTOLOGY; INFECTION CONTROL; METHODOLOGY; MIDDLE AGED; ORGANIZATION AND MANAGEMENT; PATIENT COMPLIANCE; POVERTY; PREGNANCY; PREGNANCY COMPLICATION; RURAL HEALTH CARE; RURAL POPULATION;

ADULT; ANTI-RETROVIRAL AGENTS; CD4-POSITIVE T-LYMPHOCYTES; COHORT STUDIES; COMMUNICABLE DISEASE CONTROL; FEMALE; HIV INFECTIONS; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PATIENT COMPLIANCE; POVERTY; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; RURAL HEALTH SERVICES; RURAL POPULATION; SOUTH AFRICA; TREATMENT OUTCOME;

EID: 79955772745     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0019201     Document Type: Article

References (36)

1. Coetzee D, Hildebrand K, Boulle A, Maartens G, Louis F, et al. (2004) Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa. AIDS 18: 887.
2. Brodt HR, Kamps BS, Gute P, Knupp B, Staszewski S, Helm EB, (1997) Changing incidence of AIDS-defining illnesses in the era of antiretroviral combination therapy. AIDS 11: 1731-8.
3. Detels R, Munoz A, McFarlane G, Kingsley LA, Margolick JB, et al. (1998) Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Multicenter AIDS Cohort Study Investigators. JAMA 280: 1497-503.
4. Egger M, May M, Chene G, Phillips AN, Ledergerber B, et al. (2002) Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 360: 119-29.
5. Hogg RS, Yip B, Chan KJ, Wood E, Craib KJ, et al. (2001) Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. JAMA 286: 2568-77.
6. J PF Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, et al. (1998) Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 338: 853-60.
7. Bussmann H, Wester CW, Ndwapi N, Grundmann N, Gaolathe T, et al. (2008) Five-year outcomes of initial patients treated in Botswana's National Antiretroviral Treatment Program. AIDS 22: 2303-11.
8. Ivers LC, Kendrick D, Doucette K, (2005) Efficacy of antiretroviral therapy programs in resource-poor settings: a meta-analysis of the published literature. Clin Infect Dis 41: 217-24.
9. Lawn SD, Myer L, Wood R, (2005) Efficacy of antiretroviral therapy in resource-poor settings: are outcomes comparable to those in the developed world? Clin Infect Dis 41: 1683-4.
10. Fox MP, Rosen S, (2010) Patient retention in antiretroviral therapy programs up to three years on treatment in sub-Saharan Africa, 2007-2009: systematic review. Trop Med Int Health 15 (Suppl): 1-15.
11. Cornell M, Grimsrud A, Fairall L, Fox MP, van Cutsem G, et al. (2010) Temporal changes in programme outcomes among adult patients initiating antiretroviral therapy across South Africa, 2002-2007. AIDS 24: 2263-2270.
12. Lawn SD, Myer L, Orrell C, Bekker LG, Wood R, (2005) Early mortality among adults accessing a community-based antiretroviral service in South Africa: implications for programme design. AIDS 19: 2141-8.
13. Amathole district municipality Draft Intergrated development plan review 2008-2009. Available: http://www.amathole.gov.za/files/documents/140508081833.pdf. Accessed 12 November 2010.
14. Statistics South Africa South Africa Census 2001. Available: http://www.statssa.gov.za/census01/html/default.asp. Accessed 12 November 2010.
15. Shisana O, Rehle T, Simbayi L, Mbelle N, South African National HIV prevalence, HIV incidence, behaviour and communication survey, 2005. Available: http://www.hsrcpress.ac.za/product.php?productid=2134&freedownload=1. Accessed 1 April 2011.
16. South African National Antiretroviral Treatment Guidelines Pretoria, South Africa National Dept of Health; 2004 Available http://www.doh.gov.za/docs/factsheets/guidelines/artguidelines04/intro.pdf. Accessed 1 April 2011.
17. World Health Organization Scaling Up Antiretroviral Therapy in Resource-limited Settings: Treatment Guidelines for a Public Health Approach. Available: http://whqlibdoc.who.int/publications/2004/9241591552.pdf. Accessed 24 November 2010.
18. Coetzee D, Boulle A, Hildebrand K, Asselman V, Van Cutsem G, (2004) Promoting adherence to antiretroviral therapy: the experience from a primary care setting in Khayelitsha, South Africa. AIDS 18 (Suppl): 27-31.
19. Nachega JB, Knowlton AR, Deluca A, Schoeman JH, Watkinson L, et al. (2006) Treatment supporter to improve adherence to antiretroviral therapy in HIV-infected South African adults. A qualitative study. J Acquir Immune Defic Syndr 43 (Suppl): 127-33.
20. Maskew M, MacPhail P, Menezes C, Rubel D, (2007) Lost to follow up: contributing factors and challenges in South African patients on antiretroviral therapy. S Afr Med J 97: 853-857.
21. Forster M, Bailey C, Brinkhof MW, Graber C, Boulle A, et al. (2008) Electronic medical record systems, data quality and loss to follow-up: survey of antiretroviral therapy programmes in resource-limited settings. Bull World Health Organ 86: 939-947.
22. Zachariah R, Teck R, Buhendwa L, Fitzerland M, Labana S, et al. (2007) Community support is associated with better antiretroviral treatment outcomes in a resource-limited rural district in Malawi. Trans R Soc Trop Med Hyg 101: 79-84.
23. Maqutu D, Zewotir T, North D, Naidoo K, Grobler A, (2010) Determinants of Optimal Adherence Over Time to Antiretroviral Therapy Amongst HIV Positive Adults in South Africa- A Longitudinal Study. AIDS Behav In press.
24. Starace F, Ammassari A, Trotta MP, Murri R, De Longis P, Izzo C, et al. (2002) Depression is a risk factor for suboptimal adherence to highly active antiretroviral therapy. J Acquir Immune Defic Syndr 31 (Suppl): 136-9.
25. Maj M, Satz P, Janssen R, Zaudig M, Starace F, et al. WHO Neuropsychiatric AIDS study, cross-sectional phase II (1994) Neuropsychological and neurological findings. Arch Gen Psychiatry 51: 51-61.
26. Chibanda D, Mangezi W, Tshimanga M, Woelk G, Rusakaniko S, et al. (2010) Postnatal depression by HIV status among women in Zimbabwe. J Womens Health 19: 2071-2077.
27. Rochat TJ, Richter LM, Doll HA, Buthelezi NP, Tomkins A, Stein A, (2006) Depression among pregnant rural South African women undergoing HIV testing. JAMA 295: 1376-1378.
28. Antelman G, Kaaya S, Wei R, Mbwambo J, Msamanga GI, et al. (2007) Depressive symptoms increase risk of HIV disease progression and mortality among women in Tanzania. J Acquir Immune Defic Syndr 44: 470-477.
29. Kranzer K, Lewis JJ, Ford N, Zeinecker J, Orrell C, et al. (2010) Treatment interruption in a primary care antiretroviral therapy program in South Africa: cohort analysis of trends and risk factors. J Acquir Immune Defic Syndr 55: 17-23.
30. Toro PL, Katyal M, Carter RJ, Myer L, El-Sadr WM, Nash D, et al. (2010) Initiation of antiretroviral therapy among pregnant women in resource-limited countries: CD4+ cell count response and program retention. AIDS 24: 515-24.
31. Kaplan R, Orrell C, Zwane E, Bekker LG, Wood R, (2008) Loss to follow-up and mortality among pregnant women referred to a community clinic for antiretroviral treatment. AIDS 22: 1679-81.
32. Ford N, Kranzer K, Hilderbrand K, Jouquet G, Goemaere E, Vlahakis N, et al. (2010) Early initiation of antiretroviral therapy and associated reduction in mortality, morbidity and defaulting in a nurse-managed, community cohort in Lesotho. AIDS 24: 2645-2650.
33. Immunological markers in HIV-infected pregnant women (1997) The European Collaborative Study and the Swiss HIV Pregnancy Cohort. AIDS 11: 1859-1865.
34. Leisegang R, Cleary S, Hislop M, Davidse A, Regensberg L, et al. (2009) Early and late direct costs in a Southern African antiretroviral treatment programme: a retrospective cohort analysis. PLoS Med 6: e1000189.
35. Leisegang R, Maartens G, Hislop M, Regensberg L, Cleary S, Improving the evidence base of Markov models used to estimate the costs of scaling up antiretroviral programmes in resource-limited settings. 2010 BMC Health Serv Res 10 (Suppl): 3.
36. Boulle A, Van Cutsem G, Hilderbrand K, Cragg C, Abrahams M, et al. (2010) Seven-year experience of a primary care antiretroviral treatment programme in Khayelitsha, South Africa. AIDS 24: 563-72.